Spevigo

(spesolimab)
Spevigo 450 MG in 7.5 ML Injection
NO BOXED WARNING

Dosage & administration

drug label

Spevigo prescribing information

prior authorization

Spevigo prior authorization resources

Most recent Spevigo prior authorization forms

View By Payer
Verified: Nov 27, 2023Cigna - Spevigo Prior Authorization Form
Verified: Nov 25, 2023Blue Cross Blue Shield of Michigan - Spevigo Prior Authorization Form (Medical Benefit)
Verified: Nov 20, 2023Aetna - Spevigo Prior Authorization Form
Complete Letter of Medical Necessity
Coverage Authorization Appeals
Learn More

Benefits investigation

BI Solution Plus Enrollment Form
Learn More

pharmacy

Spevigo preferred pharmacy

Pharmacy List

patient education

Spevigo patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Spevigo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Spevigo FAQs

What is the risk of using SPEVIGO during pregnancy?The limited data on the use of SPEVIGO in pregnant women are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. However, human IgG is known to cross the placental barrier, so SPEVIGO may be transmitted from the mother to the developing fetus. In an animal reproduction study, intravenous administration of a surrogate antibody against IL36R in mice during the period of organogenesis did not elicit any reproductive toxicity.
What is the estimated background risk of birth defects and miscarriage for the indicated population?The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Is SPEVIGO safe to use during lactation?There are no data on the presence of spesolimab-sbzo in human milk, the effects on the breastfed infant, or the effects on milk production. However, spesolimab-sbzo is a monoclonal antibody and is expected to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SPEVIGO and any potential adverse effects on the breastfed infant from SPEVIGO or from the underlying maternal condition.
Is SPEVIGO safe to use in pediatric patients?The safety and effectiveness of SPEVIGO in pediatric patients have not been established.
Is there a difference in safety profile between elderly and younger patients using SPEVIGO?Clinical studies of SPEVIGO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult subjects.
FAQ Data Source